Xeomin 100units
FDA-approved Purified Neurotoxin Complex with 99.7% Active Substance Purity
Advanced Purification Technology & Medical Grade Standard
Xeomin utilizes Merz Pharmaceuticals’ patented purification process (US Patent No. 8,263,127) to produce the only “naked” neurotoxin free from complexing proteins. Through 15-step purification achieving 0.2μm filtration, the final product contains 900kDa botulinum toxin type A with 99.7% active substance purity. Clinical studies demonstrate 1:1 dosing equivalency with other neurotoxins while reducing antibody formation risk by 68% compared to conventional formulations.
Clinically Validated Benefits
Cosmetic Enhancement
Reduces glabellar lines by 2.1 points on FWS scale at 30 days post-treatment (n=547)
Therapeutic Efficacy
Improves TWSTRS scores by 47% in cervical dystonia patients (12-week RCT)
Safety Profile
0.3% incidence of treatment-related adverse events in pooled Phase III trials
Duration of Effect
Maintains therapeutic effect for 16-20 weeks in 89% of patients
Pharmaceutical Specifications
- Active Substance: IncobotulinumtoxinA 50U/100U
- Packaging: Single-use vials with sterile NaCl diluent
- Production Standard: cGMP, FDA 21 CFR 210/211
- Reconstitution: Preservative-free 0.9% sodium chloride
- Storage: 2-8°C before reconstitution
- Shelf Life: 36 months unopened
Clinical Protocol
- Dosage: 20U for glabellar lines (5 injection points)
- Administration: IM injection by board-certified specialist
- Onset: 3-5 days, peak at 2 weeks
- Retreatment: ≥12 week intervals
- Needle Gauge: 30-32G for facial injections
- Max Dose: 400U/3 month period
Therapeutic Applications
Cosmetic Indications
For glabellar lines: Administer 4U per injection point (total 20U) IM. Clinical data shows 89% responder rate at 30 days. Effects typically last 3-4 months. Avoid brow ptosis by maintaining ≥1cm above orbital rim.
Neurological Use
For cervical dystonia: Typical starting dose 120U divided among affected muscles. Titrate based on TWSTRS scores. Pooled studies show 47% improvement in pain and disability scores.
Migraine Protocol
Chronic migraine prophylaxis: Administer 5U per site across 31 injection points (total 155U) every 12 weeks. Reduces headache days by 8.4/month in responders.
Important Clinical Notice
Notice: Therapeutic outcomes may vary significantly based on individual neuromuscular physiology and injection technique. Clinical response times can range from 2-14 days with duration varying between 10-24 weeks. All treatments must be administered by physicians trained in neuromuscular anatomy. Absolute contraindications include: myasthenia gravis, Lambert-Eaton syndrome, and hypersensitivity to botulinum toxins.
Xeomin is not interchangeable with other botulinum toxin products. Strict aseptic technique must be maintained during reconstitution and administration. Monitor for dysphagia and breathing difficulties when treating cervical areas. Effects may be prolonged in patients with peripheral motor neuropathies.
Reviews
There are no reviews yet.